Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
6 clinical trials · Condition
◉ Watch Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589) | National Cancer Institute (NCI) | 2022-06-30 |
| Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (NCT05114421) | M.D. Anderson Cancer Center | 2021-11-09 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800) | National Cancer Institute (NCI) | 2021-06-10 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
Track Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.